Acurx Pharmaceuticals closed at $1.02 on Nov 3, down 4.67%, within 0.0% of its 52-week closing low. Volume of 207.2K shares was 2.93× its 20-day average (well above normal).
Split-adjusted performance: -22.1% over one month, -49.0% over six months, -79.7% over one year.
Short interest was 90.8K shares at the Oct 15 settlement, down 18.7% from the prior report (1.8% of float, 1.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ACXPAcurx Pharmaceuticals | $1.02 | −4.67% | −49.0% | — | — | — | $5.6M | |
| SCNXScienture Holdings | $3.45 | +6.81% | −64.7% | — | −821.3% | — | $5.7M | Compare |
| LGVNLongeveron | $1.78 | +4.09% | −79.2% | −9.2% | −2116.0% | — | $5.7M | Compare |
| PCSAProcessa Pharmaceuticals | $1.94 | +4.86% | −27.1% | — | — | — | $5.4M | Compare |
| SKYESkye Bioscience | $1.22 | −7.58% | −82.6% | — | — | — | $5.4M | Compare |
| AZTRAzitra | $0.8838 | +5.68% | −64.1% | — | — | — | $5.4M | Compare |
| XBIOXenetic Biosciences | $2.08 | +0.97% | −32.7% | +12.0% | −140.7% | — | $4.9M | Compare |
| PULMPulmatrix | $1.33 | −5.00% | −2.2% | — | — | — | $4.9M | Compare |
| APREAprea Therapeutics | $0.5150 | +4.89% | −38.9% | −100.0% | — | — | $6.5M | Compare |
No recent articles focused on Acurx Pharmaceuticals.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
